A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）
A phase 3 trial testing YL201 in non-small-cell lung cancer, active and no longer recruiting.
Overview
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302） is a phase 3 interventional study registered as NCT06612151, led by MediLink Therapeutics (Suzhou), and active but no longer recruiting when checked on 2026-09-11. Official title: A Multicenter, Randomised, Controlled, Open-label, Phase III Study to Compare the Efficacy and Safety of YL201 Versus Topotecan Hydrochloride in Subjects With Relapsed Small Cell Lung Cancer. Planned enrolment is 438 participants (estimated). The study started in 2024-12-17 and primary completion is expected in 2027-12-01. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
Shares YL201, MediLink Therapeutics, Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialA Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)
Shares YL201, MediLink Therapeutics and the tag ctgov-ingest.
- TrialPivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
Shares MediLink Therapeutics, Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialYL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
Shares MediLink Therapeutics and the tag ctgov-ingest.
- TrialSSGJ-707 in Advanced Non-Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Shares Non-small-cell lung cancer and the tag ctgov-ingest.